CLEAR
Your source for biosimilars information, including: the basics, value, approval, manufacturing, and prescribing
Last updated August 2019

Biosimilars cost savings: a valuable impact on health care cost

Biosimilars are expected to have a robust impact on lowering health care costs

  • Biosimilars are expected to save the EU up to $44B in health care costs by 2020.1
  • Over the next five to 10 years in the US, it is estimated that biosimilars can save the health care system approximately $150B.2

The value of biosimilars in the marketplace

  • Biosimilars offer the opportunity for system-wide cost savings.
  • The introduction of biosimilars can provide headroom for greater investment in innovator products.
  • Biosimilars can provide more treatment options to patients with serious illnesses.

References: 1. Inside Sources. Europe Demonstrates Benefits of a Strong Biosimilars Marketplace. www.insidesources.com/europe-demonstrates-benefits-strong-biosimilars-marketplace/. Accessed December 21, 2018. 2. Grewal S, Ramsay S, Balu S, Carlson JJ. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Rev of Pharmacoecon Outcomes Res. 2018;18:447-454. 3. The Biosimilars Council. Biosimilars in the United States. Providing More Patients Greater Access to Lifesaving Medicines. www.biosimilarscouncil.org/wp-content/uploads/2017/09/Biosimilars-Council-Patient-Access-Study_090917.pdf. Accessed December 21, 2018.